Peter Borchmann, MD

Peter Borchmann, MD, discusses the main takeaways from the GHSG HD21 study presented at the 2024 ASCO Annual Meeting.

Peter Borchmann, MD, discusses the safety signals seen so far in the phase II JULIET trial investigating tisagenlecleucel, a chimeric antigen receptor T-cell therapy, as a treatment option for patients with diffuse large B-cell lymphoma.